Good day, and welcome to the Altimmune Incorporated Second Quarter 2017 Earnings Conference Call. Today’s conference is being recorded. At this time, I’d like to turn the conference over to Matt Duffy from LifeSci Advisors. Please go ahead.

Thank you, Matt, thank you, everyone, for participating in today’s second quarter 2017 earnings conference call. Leading the call will be Bill Enright, Chief Executive Officer of Altimmune; and Elizabeth Czerepak, Altimmune’s Chief Financial Officer. A press release with the company’s second quarter financial results can be found on the Investor page of the company’s website. Before we begin, I would like to remind everyone that remarks about future expectations, plans and prospects constitute forward-looking statements for the purposes of Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Altimmune cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated. For discussion of some of the risks and risk factors that could affect the company’s future result, please see the risk factors and other cautionary statements contained in the company’s filings with the Securities and Exchange. I would also direct you to read the forward-looking statements disclaimer in our quarterly earnings release, which is now available on our website. Any forward-looking statements made on this conference call speaks only as of today’s date, Thursday, August 10, 2017, and the company does not undertake any obligation to update any of these forward-looking statements to reflect events or circumstances that occur on or after today’s date. As a reminder, this conference call is being recorded and will be available for audio rebroadcast on Altimmune’s website, www.altimmune.com. As the operator mentioned, all participants are currently in a listen-only mode, and there will be a brief Q&A session following the company’s prepared remarks. With that, I would like to now turn the call over to Bill Enright, CEO of Altimmune. Bill, go ahead.

Thank you, Matt, and good morning to everyone joining. I’m really excited to provide you with an update on Altimmune’s progress and our accomplishments. Joining me on the call today is our Chief Financial Officer, Elizabeth Czerepak, who will review our second quarter 2017 financials. Since this is our first public call since the closing of the merger with PharmAthene in May of this year, the merger has really allowed us to create a fully integrated and diversified immunotherapeutics company with four clinical-stage assets and one preclinical asset. These assets are built off of two novel platform technologies that we call RespirVec and Densigen. We expect that our public listing on the NASDAQ global market will provide us with better access to financing to satisfy our future capital needs, which is essential to the continued development of our clinical programs, including NasoVAX, HepTcell, NasoShield and SparVax-L. We are sufficiently capitalized with $8.4 million in cash at the end of the quarter, which together with our committed financing, revenue from ongoing government contracts with BARDA and NIAID and expected a tax refund next year, we believe will be sufficient to fund us through the second quarter of 2018, and importantly, through multiple clinical milestones. A brief comment on the integration. This is going really smoothly. Given the close proximity of the geographies of the two companies, we were able to bring the key technical personnel on Board to continue to manage the SparVax-L program. We consolidated facilities to our Gaithersburg location and have officially closed the Annapolis facility. We’re also able to gain some of efficiencies during the reduction of redundancies in G&A. So now I’d like to take a moment and move on to these promising programs that I mentioned. I’ll start with NasoVAX, which is our intranasally administered recombinant…

Thank you, Bill, and good morning, everyone. For today’s call, I will provide an update regarding our second quarter 2017 financial results. Altimmune revenues for the second quarter of 2017 were approximately $3 million, consisting primarily of contract revenue from BARDA for our anthrax vaccine product candidate. During July 2016, we signed a new contract with BARDA, resulting in an increase in contract revenue of $1.9 million during the three months ended June 30, 2017, as compared to the same period in 2016. Revenues during the quarter also included $0.4 million in revenues from a contract with NIAID that was acquired from the merger with PharmAthene. Research and development operating expenses were $5.3 million for the second quarter of 2017, compared to $1.4 million in the same period last year. The increase was a result of an additional $0.5 million in research and development expenses for SparVax-L, an increase of $1.5 million in spending on the development of the NasoShield asset on behalf of BARDA, an increase of $1.0 million in HepTcell development and Phase 1 trial cost, in addition to an increase of $1.0 million in manufacturing and other costs in preparation for the NasoVAX Phase 2 trial. General and administrative expenses were $1.8 million for the second quarter of 2017, compared to $1.0 million for the same period last year. The increase was the combined result of the addition of expenses from the mergers with PharmAthene during the three months ended June 30, 2017, an increase in legal and professional costs, primarily as a result of the merger and these were partially offset by a decrease in other costs during those periods. Net loss attributable to common shareholders for the three months ended June 30, 2017 was $3.2 million, compared with $1.7 million in the same period in 2016. As of June 30, 2017, we had approximately $8.4 million in cash and cash equivalent. We believe that this amount together with committed funding and expected revenue and tax refunds is sufficient to support our operations through the second quarter of 2018. We had approximately $15.4 million common shares outstanding at June 30, 2017. For further details on our financials, including the financial results for the three and six month periods ending June 30, 2017 and 2016, please refer to our 10-Q, which is expected to be filed with the SEC shortly. And now, I’d like to turn the call back over to Bill. Bill?

Thank you, and thank you, everyone, for joining us on our first earnings call as Altimmune. We look forward to providing you with regular updates. I’d like to thank our employees for the tremendous work they put in and our Board and shareholders for their ongoing support. With that, I’d like to open the call now for Q&A. Operator?

Thank you. [Operator Instructions] And we will take our question from David Sherman with LifeSci Capital.

Hi, guys, thanks for taking my question. You had mentioned earlier in broader protection with the influenza vaccine, I was just wondering, if you could elaborate on the preclinical studies to support that?

Sure. David, thanks very much for asking the question. So, we’ve got a great deal of preclinical support in mice and parrots and other preclinical models, where we’ve been looking at this our early response. And it’s really the intranasal administration of the adenovector is really key in both the early protection and the broad response that we’re seeing. And what we’ve seen is that, we can get protection with a single intranasally administered dose as quickly as 24 to 48 hours after administering the vaccine. And that protection is pretty long-lasting, which is another key beneficiary of our vaccines. And the other nice thing about this is that, the response is very broad. So when we vaccinate using, for instance, in H1 strain of the vaccine, we’re able to show protection against multiple strains either other H1 strains that are typically non-cross-reactive, or H3, or H5, or H7, we’re getting that kind of broad universal life protection.

Okay. Thanks.

And with no more questions in the queue, that will conclude our call for today. Thank you for your participation. You may now disconnect.